2 型糖尿病的治疗，生活方式，GLP1 激动剂和 DPP4 抑制剂。
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.
机构信息
Gerald H Tomkin, Diabetes Institute of Ireland, Beacon Hospital, Sandyford, Dublin 18, Ireland.
出版信息
World J Diabetes. 2014 Oct 15;5(5):636-50. doi: 10.4239/wjd.v5.i5.636.
Abstract
In recent years the treatment focus for type 2 diabetes has shifted to prevention by lifestyle change and to more aggressive reduction of blood sugars during the early stage of treatment. Weight reduction is an important goal for many people with type 2 diabetes. Bariatric surgery is no longer considered a last resort treatment. Glucagon-like peptide-1 agonists given by injection are emerging as a useful treatment since they not only lower blood sugar but are associated with a modest weight reduction. The role of the oral dipeptidyl peptidase 4 inhibitors is emerging as second line treatment ahead of sulphonylureas due to a possible beneficial effect on the beta cell and weight neutrality. Drugs which inhibit glucose re-absorption in the kidney, sodium/glucose co-transport 2 inhibitors, may have a role in the treatment of diabetes. Insulin treatment still remains the cornerstone of treatment in many patients with type 2 diabetes.
摘要
近年来，2 型糖尿病的治疗重点已转向通过生活方式改变进行预防，以及在治疗早期更积极地降低血糖。减肥是许多 2 型糖尿病患者的重要目标。减重手术不再被视为最后的治疗手段。注射用胰高血糖素样肽-1 激动剂作为一种有用的治疗方法正在出现，因为它们不仅能降低血糖，而且与适度的体重减轻有关。由于可能对β细胞有有益作用和体重中性，口服二肽基肽酶 4 抑制剂的作用正在成为磺酰脲类药物的二线治疗。抑制肾脏葡萄糖重吸收的药物，钠/葡萄糖协同转运蛋白 2 抑制剂，可能在糖尿病的治疗中发挥作用。胰岛素治疗仍然是许多 2 型糖尿病患者治疗的基石。
相似文献
1
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.2 型糖尿病的治疗，生活方式，GLP1 激动剂和 DPP4 抑制剂。
World J Diabetes. 2014 Oct 15;5(5):636-50. doi: 10.4239/wjd.v5.i5.636.
2
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.2 型糖尿病的二线降糖治疗。
Curr Diab Rep. 2019 Jul 8;19(8):54. doi: 10.1007/s11892-019-1171-0.
3
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
4
Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.2型糖尿病合并动脉高血压患者的血压控制。钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂的重要辅助作用。
Pharmacol Res. 2020 Oct;160:105052. doi: 10.1016/j.phrs.2020.105052. Epub 2020 Jul 8.
5
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.新型降糖药物对 2 型糖尿病患者体重的影响。
Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54. doi: 10.1016/j.jcjd.2015.09.090.
6
A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.一种基于二肽基肽酶 4 的新型多表位疫苗可通过在 C57BL/6J 小鼠中产生抗 DPP4 抗体和免疫调节作用来预防链脲佐菌素诱导的糖尿病。
Biomed Pharmacother. 2017 May;89:1467-1475. doi: 10.1016/j.biopha.2017.01.089. Epub 2017 Mar 31.
7
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的心血管结局临床试验的临床意义。
Atherosclerosis. 2018 May;272:33-40. doi: 10.1016/j.atherosclerosis.2018.03.013. Epub 2018 Mar 8.
8
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
9
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.二肽基肽酶抑制剂在 2 型糖尿病中的治疗作用：对肠促胰岛素轴的控制和对餐后血糖及脂代谢的调节。
Peptides. 2018 Feb;100:158-164. doi: 10.1016/j.peptides.2017.11.023.
10
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.2 型糖尿病治疗进展：关注心血管和肾脏结局。
Med J Aust. 2020 Feb;212(3):133-139. doi: 10.5694/mja2.50472. Epub 2020 Jan 7.
引用本文的文献
1
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.GWAS 分析 476326 名个体的随机血糖水平，为糖尿病的病理生理学、并发症和治疗分层提供了新见解。
Nat Genet. 2023 Sep;55(9):1448-1461. doi: 10.1038/s41588-023-01462-3. Epub 2023 Sep 7.
2
Roles of hepatic atypical protein kinase C hyperactivity and hyperinsulinemia in insulin-resistant forms of obesity and type 2 diabetes mellitus.肝脏非典型蛋白激酶C活性亢进和高胰岛素血症在肥胖和2型糖尿病胰岛素抵抗形式中的作用。
MedComm (2020). 2021 Feb 25;2(1):3-16. doi: 10.1002/mco2.54. eCollection 2021 Mar.
3
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.2型糖尿病流行病学、病因学、发病机制、治疗及未来展望的当前趋势综述
Diabetes Metab Syndr Obes. 2021 Aug 10;14:3567-3602. doi: 10.2147/DMSO.S319895. eCollection 2021.
4
Alpha cell regulation of beta cell function.α 细胞对 β 细胞功能的调节。
Diabetologia. 2020 Oct;63(10):2064-2075. doi: 10.1007/s00125-020-05196-3. Epub 2020 Sep 7.
5
Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications.特殊促消退脂质介质：对糖尿病相关心脏、肾脏和视网膜血管并发症的调节作用
Front Pharmacol. 2018 Dec 19;9:1488. doi: 10.3389/fphar.2018.01488. eCollection 2018.
6
Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice.微生物产生的胰高血糖素样肽1可改善小鼠的葡萄糖耐量。
Mol Metab. 2016 Jun 22;5(8):725-730. doi: 10.1016/j.molmet.2016.06.006. eCollection 2016 Aug.
7
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?降糖药物的肾脏保护作用：我们有支持性数据吗？
J Clin Med. 2015 Oct 23;4(10):1866-89. doi: 10.3390/jcm4101866.
本文引用的文献
1
Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.2 型糖尿病的短期强化胰岛素治疗：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2013 Sep;1(1):28-34. doi: 10.1016/S2213-8587(13)70006-8. Epub 2013 Feb 4.
2
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.达格列净单药治疗初治亚洲2型糖尿病患者：一项随机、双盲、前瞻性III期研究。
Clin Ther. 2014 Jan 1;36(1):84-100.e9. doi: 10.1016/j.clinthera.2013.11.002. Epub 2013 Dec 28.
3
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.阿格列汀：一种用于治疗 2 型糖尿病的新型二肽基肽酶-4 抑制剂。
Am J Health Syst Pharm. 2014 Jan 15;71(2):103-9. doi: 10.2146/ajhp130131.
4
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.胰高血糖素样肽-1受体激动剂的胰腺外效应：聚焦于心血管系统、胃肠道和中枢神经系统
Diabetes Obes Metab. 2014 Aug;16(8):673-88. doi: 10.1111/dom.12251. Epub 2014 Jan 16.
5
Lixisenatide as add-on therapy to basal insulin.利司那肽作为基础胰岛素的附加治疗
Drug Des Devel Ther. 2013 Dec 13;8:25-38. doi: 10.2147/DDDT.S45108.
6
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.胰高血糖素样肽 1 类似物治疗可直接调节 2 型糖尿病患者固有免疫介导的炎症。
Diabetologia. 2014 Apr;57(4):781-4. doi: 10.1007/s00125-013-3145-0. Epub 2013 Dec 21.
7
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.胰高血糖素样肽 1 对食欲和体重的影响：重点关注中枢神经系统。
J Endocrinol. 2014 Mar 7;221(1):T1-16. doi: 10.1530/JOE-13-0414. Print 2014 Apr.
8
Comparative effectiveness of bariatric surgery vs. nonsurgical treatment of type 2 diabetes among severely obese adults.肥胖成年人中减重手术与非手术治疗 2 型糖尿病的疗效比较。
Obes Res Clin Pract. 2013 Jul-Aug;7(4):e258-68. doi: 10.1016/j.orcp.2012.08.196.
9
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.维格列汀治疗二甲双胍和磺脲类药物控制不佳的 2 型糖尿病患者的疗效和安全性。
Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.
10
Teneligliptin for the treatment of type 2 diabetes.替奈利肽治疗2型糖尿病。
Drugs Today (Barc). 2013 Oct;49(10):615-29. doi: 10.1358/dot.2013.49.10.2035882.
Zotero 插件